Success Metrics

Clinical Success Rate
93.0%

Based on 172 completed trials

Completion Rate
93%(172/185)
Active Trials
21(8%)
Results Posted
36%(62 trials)
Terminated
13(5%)

Phase Distribution

Ph phase_4
63
24%
Ph not_applicable
63
24%
Ph phase_1
26
10%
Ph phase_2
43
16%
Ph phase_3
33
13%
Ph early_phase_1
15
6%

Phase Distribution

41

Early Stage

43

Mid Stage

96

Late Stage

Phase Distribution243 total trials
Early Phase 1First-in-human
15(6.2%)
Phase 1Safety & dosage
26(10.7%)
Phase 2Efficacy & side effects
43(17.7%)
Phase 3Large-scale testing
33(13.6%)
Phase 4Post-market surveillance
63(25.9%)
N/ANon-phased studies
63(25.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

85.6%

172 of 201 finished

Non-Completion Rate

14.4%

29 ended early

Currently Active

21

trials recruiting

Total Trials

262

all time

Status Distribution
Active(23)
Completed(172)
Terminated(29)
Other(38)

Detailed Status

Completed172
unknown38
Withdrawn16
Recruiting14
Terminated13
Active, not recruiting7

Development Timeline

Analytics

Development Status

Total Trials
262
Active
21
Success Rate
93.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 115 (6.2%)
Phase 126 (10.7%)
Phase 243 (17.7%)
Phase 333 (13.6%)
Phase 463 (25.9%)
N/A63 (25.9%)

Trials by Status

active_not_recruiting73%
not_yet_recruiting21%
completed17266%
recruiting145%
terminated135%
unknown3815%
withdrawn166%

Recent Activity

Clinical Trials (262)

Showing 20 of 262 trialsScroll for more
NCT07628556

Antidiabetic Medications and Risk of Cancer

Completed
NCT06111586Phase 2

FrexalimAB in Preservation of Endogenous insULIN Secretion Compared to Placebo in adUlts and Adolescents on Top of inSulin Therapy (FABULINUS)

Recruiting
NCT00445627

Effect of Short-Term Beta-Cell Rest in Adolescents and Young Adults With Type 2 Diabetes Mellitus

Completed
NCT03899402Phase 2

Triple Therapy in T1DM

Active Not Recruiting
NCT07259564Phase 2

A Study of GS3-007a for Oral Suspension in the Diagnosis of Adult Growth Hormone Deficiency (AGHD)

Terminated
NCT02486341Not Applicable

Daily Glycaemic Variability in Frail or Disabled Older Patients With Diabetes Over 75 Treated With Basal Insulin

Completed
NCT07494084Phase 4

Sleep Loss and Circadian Misalignment - Mechanisms of Insulin Resistance

Not Yet Recruiting
NCT07460336Not Applicable

Effects of Cofrogliptin on Beta-Cell Function in LADA Patients

Not Yet Recruiting
NCT03510078Not Applicable

Intensive Versus Conventional Hyperglycemic Control in Hospitalized Non-critically Ill Patients

Completed
NCT07293715Phase 4

Permissive Versus Strict Intrapartum Glucose Management in Type 1 Diabetes (PRISM-T1D)

Recruiting
NCT07548996Phase 2

Open-Label Study of Dimethyl Fumarate in Adults With Type 1 Diabetes

Recruiting
NCT06392854Early Phase 1

Regional Lipolysis Insulin Regulation

Recruiting
NCT06699810Phase 4

Modeling Ketosis-Prone Diabetes Remission Via Diverse Mechanisms of Glucotoxicity

Active Not Recruiting
NCT03527537Phase 4

Gestational Diabetes and Pharmacotherapy (GAP)

Active Not Recruiting
NCT02176681Phase 4

A Prospective, Multicenter, Randomized, Open-label Study of 12 Week Duration to Evaluate the Effect of VILDagliptin Added to Insulin on Glycaemic Control in haemoDIALyzed Patients With Type 2 Diabetes: Probe Analysis of CGM

Completed
NCT06762314Phase 2

Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes

Recruiting
NCT04876079Not Applicable

Prevention of Mild-to-moderate Hypoglycemia in Type 1 Diabetes

Completed
NCT05258292

Glycemic Variations During the Menstrual Cycle in Women With Type 1 Diabetes

Recruiting
NCT05692739Phase 4

Clinical Trial To Determine The Effectiveness And Safety Of Topical Insulin In Dry Eye

Completed
NCT02653092Not Applicable

Reprometabolic Syndrome Mediates Subfertility in Obesity

Active Not Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
262